nach oben

Annals of Nuclear Medicine

Erschienen in:

01.11.2010 | Review Article

Nuclear neuroimaging in acute and subacute ischemic stroke

verfasst von: Naohiko Oku, Toru Kashiwagi, Jun Hatazawa

Erschienen in: Annals of Nuclear Medicine | Ausgabe 9/2010

Einloggen, um Zugang zu erhalten

Abstract

Neuroimaging in ischemic stroke continues to be one of the most developing fields in nuclear medicine. Many studies have established the efficacy of blood flow and metabolism measurements in acute ischemic stroke. Although the release of recombinant tissue plasminogen activator in clinical practice has minimized the use of SPECT or PET in the first few hours of ischemic stroke onset, implementing these techniques into a set of initial examinations is still beneficial to exclude risky patients for reperfusion therapy beyond several hours after onset. Rescuing of viable tissue suffering ischemic penumbra is an important target of early therapeutic strategy. Ischemic penumbra can be visualized by means of perfusion imaging, central type benzodiazepine receptor imaging, and hypoxy imaging. In the later phase of subacute ischemic stroke, inflammation and apoptosis can be visualized by means of peripheral-type benzodiazepine receptor imaging and annexin V imaging, respectively. Imaging of the penumbra and cellular responses will help evaluate the effects of drugs and interventions for ischemic stroke, suggesting its potential as a marker of the efficacy of future therapeutic regimens.

Friedman PJ, Davis G, Allen B. Semi-quantitative SPECT scanning in acute ischaemic stroke. Scand J Rehabil Med. 1993;25:99–105.PubMed

Mahagne MH, Darcourt J, Migneco O, Fournier JP, Thiercelin D, Ducoeur S, et al. Early ^99mTc-ethylcysteinate dimer brain SPECT patterns in the acute phase of stroke as predictors of neurological recovery. Cerebrovasc Dis. 2000;10:364–73.PubMedCrossRef

Alexandrov AV, Ehrlich LE, Bladin CF, Norris JW. Noninvasive assessment of intracranial perfusion in acute cerebral ischemia. J Neuroimaging. 1995;5:76–82.PubMed

Giubilei F, Lenzi GL, Di Pielo V, Pozzilli C, Pantano P, Bastianello S, et al. Predictive value of brain perfusion single-photon emission computed tomography in acute ischemic stroke. Stroke. 1990;21:895–900.PubMed

Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European cooperative acute stroke study (ECASS). JAMA. 1995;274:1017–25.PubMedCrossRef

Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: A randomized controlled trial. JAMA. 1999;282:2019–26.PubMedCrossRef

Acute Stroke Imaging Standardization Group-Japan. Procedure guidelines for acute stroke imaging 2007. Tokyo: Nankodo; 2007.

Ito H, Kanno I, Fukuda H. Human cerebral circulation: positron emission tomography studies. Ann Nucl Med. 2005;19:65–74.PubMedCrossRef

Okazawa H, Kudo T. Clinical impact of hemodynamic parameter measurement for cerebrovascular disease using positron emission tomography and ¹⁵O-labeled tracers. Ann Nucl Med. 2009;23:217–27.PubMedCrossRef

10.

Baron JC, Bousser MG, Rey A, Guillard A, Comar D, Castaigne P. Reversal of focal “misery-perfusion syndrome” by extra-intra-cranial arterial bypass in hemodynamic cerebral ischemia. A case study with ¹⁵O positron emission tomography. Stroke. 1981;12:454–9.PubMed

11.

Powers WJ, Raichle ME. Positron emission tomography and its application to the study of cerebrovascular disease in man. Stroke. 1985;16:361–76.PubMed

12.

Mohr JP, Barnett HJM. Classification of ischemic strokes. In: Barnett HJM, Stein BM, Mohr JP, Yatsu FM, editors. Stroke: pathophysiology, diagnosis, and management, vol. 1. New York: Churchill Livingston; 1986. p. 281–91.

13.

Minematsu K, Yamaguchi T, Omae T. ‘Spectacular shrinking deficit’: rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology. 1992;42:157–62.PubMed

14.

Olsen TS, Larsen B, Skriver EB, Herning M, Enevoldsen E, Lassen NA. Focal cerebral hyperemia in acute stroke. Incidence, pathophysiology and clinical significance. Stroke. 1981;12:598–607.PubMed

15.

Marchal G, Young AR, Baron JC. Early postischemic hyperperfusion: pathophysiologic insights from positron emission tomography. J Cereb Blood Flow Metab. 1999;19:467–82.PubMedCrossRef

16.

Baird AE, Donnan GA, Austin MC, McKay WJ. Early reperfusion in the ‘spectacular shrinking deficit’ demonstrated by single-photon emission computed tomography. Neurology. 1995;45:1335–9.PubMed

17.

Marchal G, Furlan M, Beaudouin V, Rioux P, Hauttement JL, Serrati C, et al. Early spontaneous hyperperfusion after stroke. A marker of favourable tissue outcome? Brain. 1996;119:409–19.PubMedCrossRef

18.

Garcia JH, Yoshida Y, Chen H, Li Y, Zhang ZG, Lian J, et al. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. Am J Pathol. 1993;142:623–35.PubMed

19.

Powers WJ, Grubb RL, Darriet D, Raichle ME. Cerebral blood flow and cerebral metabolic rate of oxygen requirements for cerebral function and viability in humans. J Cereb Blood Flow Metab. 1985;5:600–8.PubMed

20.

Higano S, Uemura K, Shishido F, Kanno I, Tomura N, Sakamoto K. Evaluation of critically perfused area in acute ischemic stroke for therapeutic reperfusion: a clinical PET study. Ann Nucl Med. 1993;7:167–71.PubMedCrossRef

21.

Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia—the ischemic penumbra. Stroke. 1981;12:723–5.PubMed

22.

Jones TH, Morawetz RB, Crowell RM, Marcoux FW, FitzGibbon SJ, DeGirolami U, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg. 1981;54:773–82.PubMedCrossRef

23.

Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology. 2008;55:310–8.PubMedCrossRef

24.

Nag S, Manias JL, Stewart DJ. Pathology and new players in the pathogenesis of brain edema. Acta Neuropathol. 2009;118:197–217.PubMedCrossRef

25.

Yeh SH, Liu RS, Hu HH, Wong WJ, Lo YK, Lai ZY, et al. Brain SPECT imaging with ^99mTc-hexamethylpropyleneamine oxime in the early detection of cerebral infarction: comparison with transmission computed tomography. Nucl Med Commun. 1986;7:873–8.PubMedCrossRef

26.

Hill TC, Holman BL, Lovett R, O’Leary DH, Front D, Magistretti P, et al. Initial experience with SPECT (single-photon computerized tomography) of the brain using N-isopropyl I-123 p-iodoamphetamine: Concise communication. J Nucl Med. 1982;23:191–5.PubMed

27.

Launes J, Nikkinen P, Lindroth L, Brownell AL, Liewendahl K, Livanainen M. Brain perfusion defect size in SPECT predicts outcome in cerebral infarction. Nucl Med Commun. 1989;10:891–900.PubMedCrossRef

28.

Watanabe Y, Takagi H, Aoki S, Sassa H. Prediction of cerebral infarct sizes by cerebral blood flow SPECT performed in the early acute stage. Ann Nucl Med. 1999;13:205–10.PubMedCrossRef

29.

Shimosegawa E, Hatazawa J, Inugami A, Fujita H, Ogawa T, Aizawa Y, et al. Cerebral infarction within six hours of onset: prediction of completed infarction with technetium-99m-HMPAO SPECT. J Nucl Med. 1994;35:1097–103.PubMed

30.

Ueda T, Hatakeyama T, Kumon Y, Sakaki S, Uraoka T. Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by initial SPECT. Stroke. 1994;25:298–303.PubMed

31.

Berrouschot J, Barthel H, Hesse S, Köster J, Knapp WH, Schneider D. Differentiation between transient ischemic attack and ischemic stroke within the first six hours after onset of symptoms by using ^99mTc-ECD-SPECT. J Cereb Blood Flow Metab. 1998;18:921–9.PubMedCrossRef

32.

Ueda T, Sakaki S, Yuh WTC, Nochide I, Ohta S. Outcome in acute stroke with successful intra-arterial thrombolysis and predictive value of initial single-photon emission-computed tomography. J Cereb Blood Flow Metab. 1999;19:99–108.PubMedCrossRef

33.

Ogasawara K, Ogawa A, Doi M, Konno H, Suzuki M, Yoshimoto T. Prediction of acute embolic stroke outcome after local intraarterial thrombolysis: Value of pretreatment and posttreatment ^99mTc-ethyl cysteinate dimer single photon emission computed tomography. J Cereb Blood Flow Metab. 2000;20:1579–86.PubMedCrossRef

34.

Iseda T, Nakano S, Yano T, Suzuki Y, Wakisaka S. Time-threshold curve determined by single photon emission CT in patients with acute middle cerebral artery occlusion. AJNR Am J Neuroradiol. 2002;23:572–6.PubMed

35.

Hirano T, Yonehara T, Inatomi Y, Hashimoto Y, Uchino M. Presence of early ischemic changes on computed tomography depends on severity and the duration of hypoperfusion. A single photon emission-computed tomographic study. Stroke. 2005;36:2601–8.PubMedCrossRef

36.

Gasparotti R, Grassi M, Mardighian D, Frigerio M, Pavia M, Liserre R, et al. Perfusion CT in patients with acute ischemic stroke treated with intra-arterial thrombolysis: predictive value of infarct core size on clinical outcome. AJNR Am J Neuroradiol. 2009;30:722–7.PubMedCrossRef

37.

Lansberg MG, Thijs VN, Bammer R, Olivot JM, Marks MP, Wechsler LR, et al. The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion. Stroke. 2008;39:2491–6.PubMedCrossRef

38.

Takasawa M, Jones PS, Guadagno JV, Christensen S, Fryer TD, Harding S, et al. How reliable is perfusion MR in acute stroke? Validation and determination of the penumbra threshold against quantitative PET. Stroke. 2008;39:870–7.PubMedCrossRef

39.

Ibaraki M, Shimosegawa E, Miura S, Takahashi K, Ito H, Kanno I, et al. PET measurements of CBF, OEF, and CMRO₂ without arterial sampling in hyperacute ischemic stroke: method and error analysis. Ann Nucl Med. 2004;18:35–44.PubMedCrossRef

40.

Kobayashi M, Okazawa H, Tsuchida T, Kawai K, Fujibayashi Y, Yonekura Y. Diagnosis of misery perfusion using noninvasive ¹⁵O gas PET. J Nucl Med. 2006;47:1581–6.PubMed

41.

Kobayashi M, Kudo T, Tsujikawa T, Isozaki M, Arai Y, Fujibayashi Y, et al. Shorter examination method for the diagnosis of misery perfusion with count-based oxygen extraction fraction elevation in ¹⁵O-gas PET. J Nucl Med. 2008;49:242–6.PubMedCrossRef

42.

Olsen TS, Larsen B, Herning M, Skriver EB, Lassen NA. Blood flow and vascular reactivity in collaterally perfused brain tissue. Evidence of an ischemic penumbra in patients with acute stroke. Stroke. 1983;14:332–41.PubMed

43.

Wise RJ, Bernardi S, Frackowiak RS, Legg NJ, Jones T. Serial observations on the pathophysiology of acute stroke. The transition from ischaemia to infarction as reflected in regional oxygen extraction. Brain. 1983;106:197–222.PubMedCrossRef

44.

Heiss WD, Huber M, Fink GR, Herholz K, Pietrzyk U, Wagner R, et al. Progressive derangement of periinfarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab. 1992;12:193–203.PubMed

45.

Hakim AM, Evans AC, Berger L, Kuwabara H, Worsley K, Marchal G, et al. The effect of nimodipine on the evolution of human cerebral infarction studied by PET. J Cereb Blood Flow Metab. 1989;9:523–34.PubMed

46.

Heiss WD, Graf R, Wienhard K, Löttgen J, Saito R, Fujita T, et al. Dynamic penumbra demonstrated by sequential multitracer PET after middle cerebral artery occlusion in cats. J Cereb Blood Flow Metab. 1994;14:892–902.PubMed

47.

Baron JC. Mapping of the ischaemic penumbra with PET: Implications for acute stroke treatment. Cerebrovasc Dis. 1999;9:193–201.PubMedCrossRef

48.

Furlan M, Marchal G, Viader F, Derlon JM, Baron JC. Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol. 1996;40:216–26.PubMedCrossRef

49.

Marchal G, Beaudouin V, Rioux P, de la Sayette V, Le Doze F, Viader F, et al. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke. A correlative PET-CT study with voxel-based data analysis. Stroke. 1996;27:599–606.

50.

Hatazawa J, Shimosegawa E, Toyoshima H, Ardekani BA, Suzuki A, Okudera T, et al. Cerebral blood volume in acute brain infarction. A combined study with dynamic susceptibility contrast MRI and ^99mTc-HMPAO-SPECT. Stroke. 1999;30:800–6.PubMed

51.

Mahagne MH, David O, Darcourt J, Migneco O, Dunac A, Chatel M, et al. Voxel-based mapping of cortical ischemic damage using Tc-99m L, l-ethyl cysteinate dimer SPECT in acute stroke. J Neuroimaging. 2004;14:23–32.PubMed

52.

Marchal G, Benali K, Iglesias S, Viader F, Derlon JM, Baron JC. Voxel-based mapping of irreversible ischaemic damage with PET in acute stroke. Brain. 1999;122:2387–400.PubMedCrossRef

53.

Connors BW, Malenka RC, Silva LR. Two inhibitory postsynaptic potentials, and GABA_A and GABA_B receptor-mediated responses in neocortex of rat and cat. J Physiol. 1988;406:443–68.PubMed

54.

d’Argy R, Persson A, Sedvall G. A quantitative cerebral and whole body autoradiographic study of a intravenously administered benzodiazepine antagonist 3H-Ro 15-1788 in mice. Psychopharmacology. 1987;92:8–13.

55.

Mazière M, Hantraye P, Kaijima M, Dodd R, Guibert B, Prenant C, et al. Visualization by positron emission tomography of apparent regional heterogeneity of central type benzodiazepine receptors in the brain of living baboons. Life Sci. 1985;36:1609–16.PubMedCrossRef

56.

Sette G, Baron JC, Young AR, Miyazawa H, Tillet I, Barré L, et al. In vivo mapping of brain benzodiazepine receptor changes by positron emission tomography after focal ischemia in the anesthetized baboon. Stroke. 1993;24:2046–57.PubMed

57.

Schwartz RD, Yu X, Wagner J, Ehrmann M, Mileson BE. Cellular regulation of the benzodiazepine/GABA receptor: arachidonic acid, calcium, and cerebral ischemia. Neuropsychopharmacology. 1992;6:119–25.PubMed

58.

Heiss WD, Grond M, Thiel A, Ghaemi M, Sobesky J, Rudolf J, et al. Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. Stroke. 1998;29:454–61.PubMed

59.

Heiss WD, Kracht LW, Thiel A, Grond M, Pawlik G. Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain. 2001;124:20–9.PubMedCrossRef

60.

Guadagno JV, Jones PS, Aigbirhio FI, Wang D, Fryer TD, Day DJ, et al. Selective neuronal loss in rescued penumbra relates to hypoperfusion. Brain. 2008;131:2666–78.PubMedCrossRef

61.

Hatazawa J, Satoh T, Shimosegawa E, Okudera T, Inugami A, Ogawa T, et al. Evaluation of cerebral infarction with iodine 123-iomazenil SPECT. J Nucl Med. 1995;36:2154–61.PubMed

62.

Nakagawara J, Sperling B, Lassen NA. Incomplete brain infarction of reperfused cortex may be quantitated with iomazenil. Stroke. 1997;28:124–32.PubMed

63.

Dong Y, Fukuyama H, Nabatame H, Yamauchi H, Shibasaki H, Yonekura Y. Assessment of benzodiazepine receptors using iodine-123-labeled iomazenil single-photon emission computed tomography in patients with ischemic cerebrovascular disease. A comparison with PET study. Stroke. 1997;28:1776–82.PubMed

64.

Saur D, Buchert R, Knab R, Weiller C, Röther J. Iomazenil-single-photon emission computed tomography reveals selective neuronal loss in magnetic resonance-defined mismatch areas. Stroke. 2006;37:2713–9.PubMedCrossRef

65.

Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res. 1983;43:1523–8.PubMed

66.

Hoffman JM, Rasey JS, Spence AM, Shaw DW, Krohn KA. Binding of the hypoxia tracer [³H]misonidazole in cerebral ischemia. Stroke. 1987;18:168–76.PubMed

67.

Mathias CJ, Welch MJ, Kilbourn MR, Jerabek PA, Patrick TB, Raichle ME, et al. Radiolabeled hypoxic cell sensitizers: tracers for assessment of ischemia. Life Sci. 1987;41:199–206.PubMedCrossRef

68.

Read SJ, Hirano T, Abbott DF, Sachinidis JI, Tochon-Danguy HJ, Chan JG, et al. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole. Neurology. 1998;51:1617–21.PubMed

69.

Read SJ, Hirano T, Abbott DF, Markus R, Sachinidis JI, Tochon-Danguy HJ, et al. The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke. Ann Neurol. 2000;48:228–35.PubMedCrossRef

70.

Markus R, Reutens DC, Kazui S, Read S, Wright P, Chambers BR, et al. Topography and temporal evolution of hypoxic viable tissue identified by 18F-fluoromisonidazole positron emission tomography in humans after ischemic stroke. Stroke. 2003;34:2646–52.PubMedCrossRef

71.

Spratt NJ, Ackerman U, Tochon-Danguy HJ, Donnan GA, Howells DW. Characterization of fluoromisonidazole binding in stroke. Stroke. 2006;37:1862–7.PubMedCrossRef

72.

Bowler JV, Wade JP, Jones BE, Nijran KS, Steiner TJ. Natural history of spontaneous reperfusion of human cerebral infarcts as assessed by ^99mTc HMPAO SPECT. J Neurol Neurosurg Psychiatry. 1998;64:90–7.PubMedCrossRef

73.

Oku N, Matsumoto M, Hashikawa K, Moriwaki H, Ishida M, Seike Y, et al. Intra-individual differences between technetium-99m-HMPAO and technetium-99m-ECD in the normal medial temporal lobe. J Nucl Med. 1997;38:1109–11.PubMed

74.

Asenbaum S, Brücke T, Pirker W, Pietrzyk U, Podreka I. Imaging of cerebral blood flow with technetium-99m-HMPAO and technetium-99m-ECD: a comparison. J Nucl Med. 1998;39:613–8.PubMed

75.

Sperling B, Lassen NA. Hyperfixation of HMPAO in subacute ischemic stroke leading to spuriously high estimates of cerebral blood flow by SPECT. Stroke. 1993;24:193–4.PubMed

76.

Cho I, Hayashida K, Imakita S, Kume N, Fukuchi K. Hemodynamic and metabolic state of hyperfixation with ^99mTc-HMPAO brain SPECT in subacute stroke. Ann Nucl Med. 2000;14:159–63.PubMedCrossRef

77.

Colamussi P, Calò G, Sbrenna S, Uccelli L, Bianchi C, Cittanti C, et al. New insights of flow-independent mechanisms of ^99mTc-HMPAO retention in nervous tissue: in vivo study. J Nucl Med. 1999;40:1556–62.PubMed

78.

Fujibayashi Y, Taniuchi H, Waki A, Yokoyama A, Ishii Y, Yonekura Y. Intracellular metabolism of 99mTc-d, l-HMPAO in vitro: a basic approach for understanding the hyperfixation mechanism in damaged brain. Nucl Med Biol. 1998;25:375–8.PubMedCrossRef

79.

Yamada N, Imakita S, Sakuma T. Value of diffusion-weighted imaging and apparent diffusion coefficient in recent cerebral infarctions: a correlative study with contrast-enhanced T1-weighted imaging. AJNR Am J Neuroradiol. 1999;20:193–8.PubMed

80.

Lassen NA, Sperling B. ^99mTc-bicisate reliably images CBF in chronic brain diseases but fails to show reflow hyperemia in subacute stroke: report of a multicenter trial of 105 cases comparing ¹³³Xe and ^99mTc-bicisate (ECD, neurolite) measured by SPECT on same day. J Cereb Blood Flow Metab. 1994;Suppl 1:S44–8.

81.

Tsuchida T, Nishizawa S, Yonekura Y, Sadato N, Iwasaki Y, Fujita T, et al. SPECT images of technetium-99m-ethyl cysteinate dimer in cerebrovascular diseases: comparison with other cerebral perfusion tracers and PET. J Nucl Med. 1994;35:27–31.PubMed

82.

Tamgac F, Moretti JL, Defer G, Weinmann P, Roussi A, Cesaro P. Non-matched images with ¹²³I-IMP and ^99mTc-bicisate single-photon emission tomography in the demonstration of focal hyperemia during the subacute phase of an ischaemic stroke. Eur J Nucl Med. 1994;21:254–7.PubMedCrossRef

83.

Shishido F, Uemura K, Inugami A, Ogawa T, Fujita H, Shimosegawa E, et al. Discrepant ^99mTc-ECD images of CBF in patients with subacute cerebral infarction: a comparison of CBF, CMRO₂ and ^99mTc-HMPAO imaging. Ann Nucl Med. 1995;9:161–6.PubMedCrossRef

84.

Ogasawara K, Ogawa A, Ezura M, Konno H, Doi M, Kuroda K, et al. Dynamic and static ^99mTc-ECD SPECT imaging of subacute cerebral infarction: comparison with ¹³³Xe SPECT. J Nucl Med. 2001;42:543–7.PubMed

85.

Walovitch RC, Cheesman EH, Maheu LJ, Hall KM. Studies of retention mechanism of the brain perfusion imaging agent ^99mTc-bicisate (^99mTc-ECD). J Cereb Blood Flow Metab. 1994;Suppl 1:S4–11.

86.

Inoue Y, Abe O, Kawakami T, Ozaki T, Inoue M, Yokoyama I, et al. Metabolism of ^99mTc-ethylcysteinate dimer in infarcted brain tissue of rats. J Nucl Med. 2001;42:802–7.PubMed

87.

Block M, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57–69.PubMedCrossRef

88.

Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387–94.PubMedCrossRef

89.

Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain. 2009;132:288–95.PubMedCrossRef

90.

Benavides J, Cornu P, Dennis T, Dubois A, Hauw JJ, MacKenzie ET, et al. Imaging of human brain lesions with an omega 3 site radioligand. Ann Neurol. 1988;24:708–12.PubMedCrossRef

91.

Gerhard A, Neumaier B, Elitok E, Glatting G, Ries V, Tomczak R, et al. In vivo imaging of activated microglia using [¹¹C]PK11195 and positron emission tomography in patients after ischemic stroke. Neuroreport. 2000;11:2957–60.PubMedCrossRef

92.

Gerhard A, Schwarz J, Myers R, Wise R, Banati RB. Evolution of microglial activation in patients after ischemic stroke: a [¹¹C](R)-PK11195 PET study. Neuroimage. 2005;24:591–5.PubMedCrossRef

93.

Price CJ, Wang D, Menon DK, Guadagno JV, Cleij M, Fryer T, et al. Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke. 2006;37:1749–53.PubMedCrossRef

94.

Rojas S, Martín A, Arranz MJ, Pareto D, Purroy J, Verdaguer E, et al. Imaging brain inflammation with [¹¹C]PK11195 by PET and induction of the peripheral-type benzodiazepine receptor after transient focal ischemia in rats. J Cereb Blood Flow Metab. 2007;27:1975–86.PubMedCrossRef

95.

Schroeter M, Dennin MA, Walberer M, Backes H, Neumaier B, Fink GR, et al. Neuroinflammation extends brain tissue at risk to vital peri-infarct tissue: a double tracer [¹¹C]PK11195- and [¹⁸F]FDG-PET study. J Cereb Blood Flow Metab. 2009;29:1216–25.PubMedCrossRef

96.

Radlinska BA, Ghinani SA, Lyon P, Jolly D, Soucy JP, Minuk J, et al. Multimodal microglia imaging of fiber tracts in acute subcortical stroke. Ann Neurol. 2009;66:825–32.PubMedCrossRef

97.

Yuan J. Neuroprotective strategies targeting apoptotic and necrotic cell death for stroke. Apoptosis. 2009;14:469–77.PubMedCrossRef

98.

Broughton BR, Reutens DC, Soby CG. Apoptotoic mechanisms after cerebral ischemia. Stroke. 2009;40:e331–9.PubMedCrossRef

99.

Seigneuret M, Devaux PF. ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes. Proc Natl Acad Sci USA. 1984;81:3751–5.PubMedCrossRef

100.

Diaz C, Schroit AJ. Role of translocases in the generation of phosphatidylserine asymmetry. J Membr Biol. 1996;151:1–9.PubMedCrossRef

101.

Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 1992;148:2207–16.PubMed

102.

Andree HA, Reutelingsperger CP, Hauptmann R, Hemker HC, Hermens WT, Willems GM. Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J Biol Chem. 1990;265:4923–8.PubMed

103.

Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995;182:1545–56.PubMedCrossRef

104.

Blankenberg FG, Kalinyak J, Liu L, Koike M, Cheng D, Goris ML, et al. ^99mTc-HYNIC-annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibody. Eur J Nucl Med Mol Imaging. 2006;33:566–74.PubMedCrossRef

105.

Lorberboym M, Blankenberg FG, Sadeh M, Lampl Y. In vivo imaging of apoptosis in patients with acute stroke: correlation with blood-brain barrier permeability. Brain Res. 2006;1103:13–9.PubMedCrossRef

Titel: Nuclear neuroimaging in acute and subacute ischemic stroke
verfasst von: Naohiko Oku
Toru Kashiwagi
Jun Hatazawa
Publikationsdatum: 01.11.2010
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 9/2010
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-010-0421-7

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2010

F-18 FDG PET/CT in relapsing polychondritis

Imaging of a rat osteoarthritis model using 18F-fluoride positron emission tomography

Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate

The management of pyothorax-associated lymphoma using 18F-FDG PET/CT

Positron emission tomography inter-scanner differences in dopamine D2 receptor binding measured with [11C]FLB457

Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patients with preserved ejection fraction